Etodolac-liquid-filled dispersion into hard gelatin capsules: An approach to improve dissolution and stability of etodolac formulation

Drug Development and Industrial Pharmacy

Volumn 32, Issue 7, 2006, Pages 865-876

  Barakat, N S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Dissolution studies; Etodolac; Gelucire 44 14; Liquid dispersion; Phase solubility study; Stability; TPGS

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; DRUG CARRIER; ETODOLAC; GELATIN; GELUCIRE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CAPSULE; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; HUMIDITY; INFRARED SPECTROSCOPY; TEMPERATURE; WATER ABSORPTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CAPSULES; CRYSTALLIZATION; DRUG CARRIERS; DRUG STABILITY; ETODOLAC; GELATIN; HUMIDITY; POLYETHYLENE GLYCOLS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TEMPERATURE; VITAMIN E;

EID: 33747609302     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500534192     Document Type: Article

References (48)

1. Balfour, J. A., & Buckley, M. T. (1991). Etodolac A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pin status. Drugs 42, 274-299.
2. Barakat, N. S. (2006). Enhanced oral etodolac absorption and the anti-inflammatory effect using Gelucire 44/14 and vitamin E-TPGS dispersion. Bull. Fac. Pharm. Cairo Univ. In press.
3. Bodmeier, R., Paeratakul, O., Chen, H., & Zhang, W. (1990). Formulation of sustained release wax matrices within hard gelatin capsules in a fluidized bed. Drug Dev. Ind. Pharm. 16, 1505-1519.
4. Craig, D. Q. M. (1990). Polyethylene glycols and drug release. Drug Dev. Ind. Pharm. 16, 2501-2526.
5. Craig, D. Q. M., & Newton, J. M. (1992). The dissolution of nortiptyline hydrochloride from PEG solid dispersions. Int. J. Pharm. 78, 175-182.
6. Corrigan, O. I., Murphy, C. A., Timoney, R. F. (1979). Dissolution properties of polyethylene glycol and PEG-drug systems. Int. J. Pharm. 4, 67-74.
7. Damian, F., Blaton, N., Naesens, L., Blazarini, J., Kinget, R., Augustijns, P., & Van den Mooter, G. (2000). Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur. J. Pharm. Sci. 10, 311-322.
8. Dennis, A. B. (1988). Sustained Drug Release from Semi-solid Capsule Formulation. Ph. D. Thesis, The Welsh School of Pharmacy, Cardiff.
9. Dennis, A. B., Farr, S. J., Kellaway, I. W., Taylor, G., & Davidson, R. (1990). Evaluation of rapid release and sustained release Gelucire capsule formulations. Int. J. Pharm. 65, 85-100.
10. Doelker, C., Doelker, E., Buri, P., & Waginaire, L. (1986). The incorporation and in vitro release profiles of liquid deliquescent or unstable drugs with fusible excipients in hard geltin capsules. Drug Dev. Ind. Pharm. 12, 1553-1565.
11. Dordunoo, S. K., Ford, J. L., & Rubinstein, M. H. (1991). Preformulation studies on solid dispersions containing triameterene or temazepam in polyethylene glycols or Gelucire 44/14 for liquid filling of hard gelatin capsules. Drug Dev. Ind. Pharm. 17, 1685-1713.
12. Dordunoo, S. K., Ford, J. L., & Rubinstein, M. H. (1996). Solidification studies of polyethylene glycols, Gelucire 44/14 or their dispersions with triamterene or temazepam. J. Pharm. Pharmacol. 48, 782-789.
13. Dubois, J. L., & Ford, J. L. (1985). Similarities in the release rate of different drugs from PEG 6000 dispersions. J. Pharm. Pharmacol. 37, 494-495.
14. Eastman Chemical Company. (1998). TPGS NF, Properties and applications, Publication EFC-226A, Kingsport, TN.
15. Equisabel, A., San Vicente, A., Igartua, M., Hernandez, R. M., Gascon, A. R., Calvo, M. B., & Pedraz, J. L. (1996). Influence of melting point and hydrophilic/lipophilic balance on the release of salbutamol sulfate from lipid matrices. ST.P. Pharma. 6, 365-369.
16. Ficarra, R., Ficarra, P., Calabro, M., & Costantino, D. (1991). Quantitative high-performance liquid chromatographic determination in pharmaceutical formulations. IL Farmaco 46, 403-407.
17. Ford, J. L. (1980). The current status of solid dispersions. Pharm. Acta Helv. 61, 69-88.
18. Gattefossé, Product literature, Gattefossé. (1999). Pharmaceutical excipient for oral semi-solid formulation, Gelucire 44/14-Prompt release and enhanced bioavailability, PF 96327, Ist Edition.
19. Ginés, J. M., Veiga, M. D., Arias, M. J., & Rabasco, A. M. (1995). Elaboration and thermal study of interaction between cinnarizine and Gelucire 53/10 physical mixtures and solid dispersions. Int. J. Pharm. 84, 161-166.
20. Grimm, W. (1998). Extension of the International Conference on harmonization tripartite guidelines for stability testing of new drug substances and products to countries of climatic zones III and IV. Drug Dev. Ind. Pharm. 24, 404-409.
21. Hancock, B. C., & Zografi, G. (1997). Characterization and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86, 1-12.
22. Henck, J.-O., Griesser, U. J., & Burger, A. (1997). Polymorphie von Arzneistoffen, Pharm. Ind. 59, 165-169.
23. Higuchi, T., & Connors, K. A. (1965). Phase solubility techniques. Adv. Anal. Chem. Instrum. 4, 117-212.
24. Howard, J. R., & Gould, P. L. (1987). Drug release from thermosetting fatty vehicles filled into hard gelatin capsules. Drug dev. Ind. Pharm. 13, 1030-1045.
25. Khan, K. A. (1975). The concept of dissolution efficiency. J. Pharm. Pharmacol. 27, 48-49.
26. Khoo, S. M., Porter, C. J. H., & Charman, W. N. (2000). The formulation of halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: physical stability and absolute bioavailability assessment. Int. J. Pharm. 205, 65-78.
27. Laine, E., Auramo, A., & Kahela, A. (1988). On the structural behavior of triglycerides with time. Int. J. Pharm. 43, 241-247.
28. Lloyd, G. R., Craig, D. Q. M., & Smith, A. (1997). An investigation into the melting behavior of binary mixes and solid dispersions of paracetamol and PEG 4000. J. Pharm. Sci. 86, 991-996.
29. Martin, L., Wilson, C. G., Koosha, F., Tetley, L., Gray, A. I., Senel, S., Uchegbu, I. F. (2002). The release of model macromolecules may be controlled by the hydrophobicity of palmitoyl glycol chitosan hydrogels. J. Control. Release 80, 87-100.
30. Passerini, N., Perissutti, B., Moneghini, M., Voinovich, D., Albertini, B., Cavallari, C., & Rodriguez, L. (2002). Characterization of carbamazepine-Gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds. J. Pharm. Sci. 91, 699-707.
31. Pinto, J. F., & Silverio, N. P. (2001). Assessment of the extrudability of three different mixtures of saturated polyglycolysed glycerides by determination of the "specific work of extrusion" and by capillary rheometry. Pharm. Dev. Technol. 6, 117-128.
32. Polli, J. E., Rekhi, G. S., Augsburger, L. L., & Shah, V. P. (1997). Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tablets. J. Pharm. Sci. 86, 690-700.
33. Rama Prasad, Y. V., Puthli, S. P., Eaimtrakarn, S., Ishida, M., Yoshikawa, Y., Shibata, N., & Takada, K. (2003). Enhanced intestinal absorption of vancomycin with labrasol and D-α-tocopheryl PEG 1000 succinate in rats. Int. J. Pharm. 250, 181-190.
34. Remunan, C., Bretal, M., Nunez, A., & Vila Jato, J. L. (1992a). Accelerated stability study of sustained release tablets prepared with Gelucire. Int. J. Pharm. 80, 151-159.
35. Remunan, C., Mrhar, A., Primozic, S., Karba, R., & Vila Jato, J. L. (1992b). Sustained nifedipine formulations: moment, modeling and simulation as pharmacokinetic analysis approach. Drug Dev. Ind. Pharm. 18, 187-202.
36. Roussin, P., & Laforet, J.-P. (1997). Investigating semi-solid formulations: physical characterization and stability study of Gelucire registered trade mark 44/14. Fram. Vestn. 48, 260-261.
37. Saers Sjökvist, E., & Craig, D. Q. M. (1992). An investigation into the mechanisms of dissolution of alkyl p-aminobenzoates from PEG solid dispersions. Int. J. Pharm. 83, 211-29.
38. Serajuddin, A. T. M. (1999). Solid dispersions of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88, 1058-1066.
39. Serajuddin, A. T. M., Sheen, P. C., Mufson, D., Bernstein, D. F., & Augustine, M. A. (1988). Effect of vehicle amphiphillicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions. J. Pharm. Sci. 77, 414-417.
40. Smith, A., Lampard, J. F., Carruthers, K. M., & Regan, P. (1990). The filling of molten ibuprofen into hard gelatin capsules. Int. J. Pharm. 59, 115-119.
41. Sutananta, W., Craig, D. Q. M., & Newton, J. M. (1994a). An investigation into the effect of preparation conditions on the structure and mechanical properties of pharmaceutical glycerides bases. Int. J. Pharm. 110, 75-91.
42. Sutananta, W., Craig, D. Q. M., Newton, J. M. (1994b). The effects of aging on the thermal behavior and mechanical properties of pharmaceutical glycerides. Int. J. Pharm. 111, 51-62.
43. Sutananta, W., Craig, D. Q. M., & Newton, J. M. (1995). An evaluation of the mechanism of drug release from glyceride bases. J. Pharm. Pharmacol. 47, 182-187.
44. Sutananta, W., Craig, D. Q. M., & Newton, J. M. (1996). The use of dielectric analysis as a means of characterizing the effects of moisture uptake by pharmaceutical glyceride bases. Int. J. Pharm. 132, 1-8.
45. Thies, C., Dos santos, I. R., Richard, J., Vandevelde, V., Rolland, H., & Benoit, J. P. (2003). A supercritical fluid-based coating technology: 1. Process considerations. J. Microencapsul. 20, 87-96.
46. Van den Mooter, G., Augustijins, P., Blaton, N., & Kinget, R. (1998). Physicochemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K 30. Int. J. Pharm. 164, 67-80.
47. Wu, S. H., & Hopkins, W. K. (1999). Characteristics of D-α-tocopheryl PEG 1000 succinatae for applications as an absorption enhancer in drug delivery systems. Pharm. Tech. 23, 52-60.
48. Yüksel, N., Karataş, A., Özkan, Y., Savaşer, A., Özkan, S. A., & Baykara, T. (2003). Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 56, 453-459.